AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31996053 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablets
Number of subjects: 0
Study 30779597 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly resistance exercise breaks (REX)
Number of subjects: 14
Study 30779597 — intervention group
Group type: COMPARATOR
Intervention: Prolonged sitting (SIT)
Number of subjects: 14
Study 28114769 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual plus common factors feedback (TAU + CFF)
Number of subjects: 79
Study 28114769 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 79
Study 23941811 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-formulation driven CBT
Number of subjects: 54
Study 25713916 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryonal natural orifice transluminal endoscopic surgery (ENOTES)
Number of subjects: 0
Study 25713916 — intervention group
Group type: COMPARATOR
Intervention: Surgery (laparotomy)
Number of subjects: 0
Study 21612965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection of steroid (betamethasone 7 mg)
Number of subjects: 70
Study 21612965 — intervention group
Group type: COMPARATOR
Intervention: Standard subacromial infiltration of 7 mg of betamethasone
Number of subjects: 70
Study 19484679 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (50 mg/day)
Number of subjects: 21
Study 19484679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ambroxol hydrochloride 45 mg/day)
Number of subjects: 21
Study 17327320 — intervention group
Group type: EXPERIMENTAL
Intervention: BFST-D
Number of subjects: 104
Study 17327320 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 104
Study 17327320 — intervention group
Group type: COMPARATOR
Intervention: Educational Support (ES)
Number of subjects: 104
Study 15513279 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g creatine monohydrate in solution
Number of subjects: 6
Study 15513279 — intervention group
Group type: COMPARATOR
Intervention: Creatine Serum (5 ml)
Number of subjects: 6
Study 15513279 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 6
Study 11599461 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) administered in vivo
Number of subjects: 88
Study 11599461 — intervention group
Group type: COMPARATOR
Intervention: No Growth Hormone (no GH)
Number of subjects: 88
Study 9689343 — intervention group
Group type: EXPERIMENTAL
Intervention: Phadiatop
Number of subjects: 8329
Study 9689343 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Prick Test (SPT)
Number of subjects: 8329
Study 9689343 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgE
Number of subjects: 8329
Study 9689343 — intervention group
Group type: COMPARATOR
Intervention: Skin Prick Test (SPT) vs Phadiatop
Number of subjects: 8329
Study 9689343 — intervention group
Group type: COMPARATOR
Intervention: Skin Prick Test (SPT) vs Total IgE
Number of subjects: 8329
Study 7991718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid biogenic amines analysis in schizophrenia
Number of subjects: 36
Study 7991718 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptic treatment
Number of subjects: 36
Study 2532790 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (50 units/kg body weight intravenously immediately after antivenom followed by a continuous infusion of 10 units/kg/hr in isotonic saline for 24 hours)
Number of subjects: 28
Study 2532790 — intervention group
Group type: COMPARATOR
Intervention: Antivenom alone
Number of subjects: 28
Study 29566539 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil tamponade in vitrectomized myopic eyes
Number of subjects: 20
Study 29566539 — intervention group
Group type: COMPARATOR
Intervention: Non-vitrectomized highly myopic eyes
Number of subjects: 20
Study 27919979 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day (arm A)
Number of subjects: 74
Study 27919979 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day + Docetaxel 75 mg/m2 (arm B)
Number of subjects: 74
Study 25265976 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (history of angina and chest pain)
Number of subjects: 4878
Study 25265976 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (past history of angina)
Number of subjects: 4878
Study 25265976 — intervention group
Group type: COMPARATOR
Intervention: Group A (no history of angina)
Number of subjects: 4878
Study 22634443 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine recipients
Number of subjects: 900
Study 22634443 — intervention group
Group type: COMPARATOR
Intervention: Placebo recipients
Number of subjects: 900
Study 22634443 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in Africa
Number of subjects: 900
Study 22634443 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in Europe
Number of subjects: 900
Study 22634443 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the US
Number of subjects: 900
Study 22634443 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in India
Number of subjects: 900
Study 22634443 — intervention group
Group type: EXPERIMENTAL
Intervention: All regions
Number of subjects: 900
Study 20406956 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular home cooking
Number of subjects: 0
Study 18029921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA)
Number of subjects: 180
Study 18029921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle capillary (FNC) sampling
Number of subjects: 180
Study 18029921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) in solid nodules
Number of subjects: 180
Study 18029921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) in mixed cystic-solid nodules
Number of subjects: 180
Study 18029921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle capillary (FNC) sampling in solid nodules
Number of subjects: 180
Study 18029921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle capillary (FNC) sampling in mixed cystic-solid nodules
Number of subjects: 180
Study 16105365 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational package delivered by midwives and health visitors
Number of subjects: 1174
Study 16105365 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1174
Study 12450893 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (NS)
Number of subjects: 15
Study 12450893 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanols (SS)
Number of subjects: 15
Study 12450893 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 mixture of sterols and stanols (NSS)
Number of subjects: 15
Study 12450893 — intervention group
Group type: COMPARATOR
Intervention: Cornstarch (control)
Number of subjects: 15
Study 10410615 — intervention group
Group type: EXPERIMENTAL
Intervention: Touched by waitress confederates
Number of subjects: 144
Study 10410615 — intervention group
Group type: COMPARATOR
Intervention: Not touched by waitress confederates
Number of subjects: 144
Study 10410615 — intervention group
Group type: EXPERIMENTAL
Intervention: Touched by waitress confederates in mixed-gender dyads
Number of subjects: 144
Study 10410615 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-gender (men-men) dyads
Number of subjects: 144
Study 7670096 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuGM‐CSF 5.0 micrograms/kg twice per day
Number of subjects: 20
Study 7670096 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuGM‐CSF 10.0 micrograms/kg once per day
Number of subjects: 20
Study 7670096 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuGM‐CSF 5.0 micrograms/kg once per day
Number of subjects: 20
Study 7670096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2208436 — intervention group
Group type: EXPERIMENTAL
Intervention: Invigorating Spleen (IS) group treated by modified Yi‐Gong‐San for 3 months
Number of subjects: 101
Study 2208436 — intervention group
Group type: COMPARATOR
Intervention: Replenishing zinc (RZ) group treated by 0.2% zinc sulphate syrup for 3 months
Number of subjects: 101
Study 7429005 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 2 x 1 g/day for 48 hours, infused over 30 or 60 minutes at 12-hour intervals
Number of subjects: 16
Study 31006644 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematically aligned (KA) TKA
Number of subjects: 14
Study 31006644 — intervention group
Group type: COMPARATOR
Intervention: Mechanically aligned (MA) TKA
Number of subjects: 14
Study 30396383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D)
Number of subjects: 60
Study 30396383 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 60
Study 30396383 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (group E)
Number of subjects: 60
Study 27121539 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week extended-release naltrexone (XR-NTX)
Number of subjects: 180
Study 27121539 — intervention group
Group type: COMPARATOR
Intervention: Daily buprenorphine-naloxone (BP-NLX)
Number of subjects: 180
Study 25225952 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-day interactive education program
Number of subjects: 76
Study 25225952 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 76
Study 21718117 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% human milk-based diet (mother's milk fortified with donor human milk-based HMF)
Number of subjects: 207
Study 21718117 — intervention group
Group type: COMPARATOR
Intervention: Bovine milk-based HMF-fortified diet
Number of subjects: 207
Study 20953684 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 5 mg + fenofibric acid 135 mg
Number of subjects: 760
Study 20953684 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 5 mg
Number of subjects: 760
Study 20953684 — intervention group
Group type: COMPARATOR
Intervention: fenofibric acid 135 mg
Number of subjects: 760
Study 18030944 — intervention group
Group type: EXPERIMENTAL
Intervention: Website intervention for chronic low back pain management
Number of subjects: 20
Study 18030944 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 patients)
Number of subjects: 20
Study 16102948 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg three-times-a-week (t.i.w.)
Number of subjects: 0
Study 16102948 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 40,000 IU weekly (q.w.)
Number of subjects: 0
Study 12110340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional vinblastine (VNB)
Number of subjects: 16
Study 12110340 — intervention group
Group type: COMPARATOR
Intervention: 3% sodium tetradecyl sulfate (STS)
Number of subjects: 16
Study 10773184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8737889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (CRL) 0.5 micrograms
Number of subjects: 25
Study 8737889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (CRL) 5 micrograms
Number of subjects: 25
Study 8737889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1482222 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine treatment (Catapres‐TTS No. 2)
Number of subjects: 375
Study 1482222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 3904334 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy diet supplemented with sodium chloride (Group I)
Number of subjects: 30
Study 3904334 — intervention group
Group type: COMPARATOR
Intervention: Energy-reduced diet with sodium restriction (Group II)
Number of subjects: 30
Study 31442250 — intervention group
Group type: EXPERIMENTAL
Intervention: Shareholder networks in Turkish companies
Number of subjects: 0
Study 31442250 — intervention group
Group type: EXPERIMENTAL
Intervention: Shareholder networks in Dutch companies
Number of subjects: 0
Study 31442250 — intervention group
Group type: COMPARATOR
Intervention: Randomised version of shareholder networks
Number of subjects: 0
Study 29663044 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day PCT algorithm with predefined cutoff values for the initiation or stoppage of antibiotics (PCT group)
Number of subjects: 302
Study 29663044 — intervention group
Group type: COMPARATOR
Intervention: Standard guidelines (control group)
Number of subjects: 302
Study 29663044 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT group
Number of subjects: 302
Study 29663044 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 302
Study 26469139 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (doxorubicin-cyclophosphamide followed by weekly paclitaxel) in arm A
Number of subjects: 945
Study 26469139 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (doxorubicin-cyclophosphamide followed by weekly paclitaxel plus trastuzumab) in arm C
Number of subjects: 945
Study 23385488 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral telephonic intervention
Number of subjects: 526
Study 23385488 — intervention group
Group type: COMPARATOR
Intervention: Print only intervention
Number of subjects: 526
Study 23426208 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Analgesia (EA)
Number of subjects: 50
Study 23426208 — intervention group
Group type: COMPARATOR
Intervention: Continuous Wound Infiltration (CWI)
Number of subjects: 50
Study 20010606 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive technique targeting reconsolidation of fear memories
Number of subjects: 0
Study 17678558 — intervention group
Group type: EXPERIMENTAL
Intervention: MeNZB+MenC
Number of subjects: 0
Study 17678558 — intervention group
Group type: COMPARATOR
Intervention: MeNZB
Number of subjects: 0
Study 16620720 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 102
Study 16620720 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 102
Study 12797485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-acquired pneumonia (HAP)
Number of subjects: 129
Study 12797485 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired pneumonia (CAP)
Number of subjects: 129
Study 12797485 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exacerbation of chronic bronchitis (AECB)
Number of subjects: 129
Study 12797485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculosis
Number of subjects: 129
Study 12797485 — intervention group
Group type: COMPARATOR
Intervention: Control group (noninfectious lung diseases)
Number of subjects: 129
Study 11001085 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA 60 mg daily for 14 days
Number of subjects: 14
Study 11001085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8803515 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 7.5 mg o.d.
Number of subjects: 201
Study 8803515 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg o.d.
Number of subjects: 201
Study 8803515 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg o.d.
Number of subjects: 201
Study 8803515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 1730810 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 and vaginal P (group I, n = 11)
Number of subjects: 31
Study 1730810 — intervention group
Group type: EXPERIMENTAL
Intervention: P only (group II, n = 11)
Number of subjects: 31
Study 1730810 — intervention group
Group type: COMPARATOR
Intervention: No E2 or P (group III, n = 9)
Number of subjects: 31
Study 31944806 — intervention group
Group type: EXPERIMENTAL
Intervention: RNT-focused acceptance and commitment therapy (ACT)
Number of subjects: 48
Study 31944806 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 48
Study 30639922 — intervention group
Group type: EXPERIMENTAL
Intervention: PATCH (100 mcg transdermal 17β-estradiol with cyclic progesterone)
Number of subjects: 117
Study 30639922 — intervention group
Group type: EXPERIMENTAL
Intervention: PILL (30 mcg ethinyl estradiol + 0.15 mg desogestrel)
Number of subjects: 117
Study 30639922 — intervention group
Group type: COMPARATOR
Intervention: E- (no estrogen)
Number of subjects: 117
Study 30639922 — intervention group
Group type: EXPERIMENTAL
Intervention: PATCH
Number of subjects: 117
Study 30639922 — intervention group
Group type: EXPERIMENTAL
Intervention: PILL
Number of subjects: 117
Study 27077214 — intervention group
Group type: EXPERIMENTAL
Intervention: Means Safety
Number of subjects: 370
Study 27077214 — intervention group
Group type: COMPARATOR
Intervention: Means Restriction
Number of subjects: 370
Study 25765132 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous tantalum monoblock cup (TM)
Number of subjects: 113
Study 25765132 — intervention group
Group type: COMPARATOR
Intervention: Porous-coated titanium monoblock cup (control)
Number of subjects: 113
Study 23815533 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss maintenance strategy
Number of subjects: 741
Study 23815533 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight stable group
Number of subjects: 741
Study 23815533 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain group
Number of subjects: 741
Study 23815533 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 741
Study 21371991 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia mobile phone intervention (STUB IT) with automated video and text messages tailored to quit date, role model, and timing over 6 months.
Number of subjects: 226
Study 21371991 — intervention group
Group type: COMPARATOR
Intervention: General health video message sent to control group every 2 weeks.
Number of subjects: 226
Study 19762153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100mg
Number of subjects: 20
Study 19762153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600mg
Number of subjects: 20
Study 19762153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 100mg
Number of subjects: 20
Study 19762153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17359512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion (CsA‐ME)
Number of subjects: 682
Study 17359512 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 682
Study 15251156 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine treatment
Number of subjects: 415
Study 15251156 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 415
Study 12514902 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular torsion
Number of subjects: 37
Study 12514902 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisperm antibodies
Number of subjects: 37
Study 12514902 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+, CD8+, and NK cells
Number of subjects: 37
Study 12514902 — intervention group
Group type: EXPERIMENTAL
Intervention: LH and/or FSH and/or testosterone levels
Number of subjects: 37
Study 12514902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal function
Number of subjects: 37
Study 9725548 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mg)
Number of subjects: 10
Study 9725548 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.6 mg)
Number of subjects: 10
Study 9725548 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.8 mg)
Number of subjects: 10
Study 9725548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7976643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cerebral hypothermia (32-33 degrees C) managed by whole body compartment cooling technique
Number of subjects: 10
Study 7976643 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of jugular venous oxygen saturation and BTT/TMT during cerebral hypothermia treatment
Number of subjects: 10
Study 2647187 — intervention group
Group type: EXPERIMENTAL
Intervention: rh GM‐CSF (recombinant human granulocyte/macrophage colony stimulating factor) administered by continuous infusion for 3‐21 days at doses of 100‐400 micrograms/m2/day
Number of subjects: 31
Study 2647187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rh GM‐CSF)
Number of subjects: 31
Study 2647187 — intervention group
Group type: EXPERIMENTAL
Intervention: rh GM‐CSF
Number of subjects: 31
Study 2647187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 30636747 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic Embitterment Scale (PTED scale)
Number of subjects: 102
Study 30636747 — intervention group
Group type: EXPERIMENTAL
Intervention: General Health Questionnaire (GHQ‐28)
Number of subjects: 102
Study 30636747 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on unemployment status
Number of subjects: 102
Study 28221207 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 2496
Study 28221207 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (TXA)
Number of subjects: 2496
Study 26467326 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (n = 508)
Number of subjects: 1292
Study 23706644 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine (2mg/kg of 2% lidocaine)
Number of subjects: 60
Study 23706644 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA lidocaine (0.15 mL/kg of 1.35% lidocaine)
Number of subjects: 60
Study 23706644 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% normal saline)
Number of subjects: 60
Study 21875912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil treatment for 12 weeks in HF+EOV subjects
Number of subjects: 56
Study 18632217 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PET
Number of subjects: 16
Study 18632217 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-MID
Number of subjects: 16
Study 18632217 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-EXP
Number of subjects: 16
Study 18632217 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-INS
Number of subjects: 16
Study 18632217 — intervention group
Group type: COMPARATOR
Intervention: D-PET
Number of subjects: 16
Study 17369602 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (A)
Number of subjects: 326
Study 17369602 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (T)
Number of subjects: 326
Study 15791370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track rehabilitation program
Number of subjects: 52